Results 11 to 20 of about 44,935 (165)

Randomised, Double-Blinded, Placebo-Controlled Challenge Test With Single Food Items in Dogs With Atopic Dermatitis and Adverse Food Reactions. [PDF]

Vet Dermatol
ABSTRACT Background Identification of offending foods in dogs with adverse food reactions is usually based on “deterioration” during open food challenges. Objectives To examine the placebo effect during double‐blinded, placebo‐controlled food challenges using a predefined set of criteria for relapse.
Sofou EI, Samuel E, Aleksandrova S, Chatzis M, Saridomichelakis MN.   +4 more
europepmc   +2 more sources

An open-label pilot study on an adsorbent mousse containing adelmidrol in client-owned cats with feline atopic skin syndrome and associated seborrhoea. [PDF]

Vet Dermatol
Background – Besides pruritus and skin lesions, cats with feline atopic skin syndrome (FASS) may have seborrhoea. Hypothesis/Objectives – The aim of this pilot study was to investigate whether an adsorbent mousse containing tapioca starch, adelmidrol and a nonpharmacological antimicrobial complex could decrease FASS‐associated seborrhoea in cats ...
Noli C, Della Valle MF, Morelli G, Schievano C, Skinalia Clinical Research Group.   +4 more
europepmc   +2 more sources

Efficacy and field safety of ilunocitinib for the control of atopic dermatitis in client-owned dogs: A multicentre, double-masked, randomised, placebo-controlled clinical trial. [PDF]

Vet Dermatol
Background – Inhibition of the Janus kinase (JAK) pathway is a well‐established option for canine atopic dermatitis (cAD). Objective – To evaluate the efficacy and safety of ilunocitinib, a novel JAK inhibitor for the control of pruritus and skin lesions in client‐owned dogs with cAD.
Forster S, Trout CM, Despa S, Boegel A, Berger D, King S.   +5 more
europepmc   +2 more sources

Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial. [PDF]

Vet Dermatol
Background: Inhibition of the Janus kinase pathway is an established treatment for allergic dermatitis. Objective: To evaluate the efficacy and safety of ilunocitinib for control of pruritus in dogs with allergic dermatitis in a randomised, double‐masked clinical trial.
Forster S, Trout CM, Despa S, Boegel A, Berger D, King S.   +5 more
europepmc   +2 more sources

Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. [PDF]

Vet Dermatol
Background – Janus kinase inhibitors (JAKi) have been shown to reduce pruritus and improve associated inflammatory skin lesions in canine atopic dermatitis (cAD). Objective – To evaluate the efficacy and safety of ilunocitinib, in comparison to oclacitinib, for the control of cAD in a randomised, blinded trial.
Forster S, Boegel A, Despa S, Trout C, King S.   +4 more
europepmc   +2 more sources

A prospective study evaluating the correlation between local weather conditions, pollen counts and pruritus of dogs with atopic dermatitis. [PDF]

Vet Dermatol
Abstract Background Canine atopic dermatitis (cAD) is a hereditary, generally pruritic and predominantly T‐cell‐driven inflammatory skin disease, involving an interplay between skin barrier abnormalities, allergen sensitisation and microbial dysbiosis.
Widorn L, Zabolotski Y, Mueller RS.
europepmc   +2 more sources

A randomised, double‐blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO‐524 in dogs with atopic dermatitis

Veterinary Dermatology, Volume 34, Issue 6, Page 523-531, December 2023., 2023
Background – Polyunsaturated fatty acids (PUFA) can be beneficial in the management of canine atopic dermatitis (cAD). A commercial product PCSO‐524 containing PUFA has demonstrated anti‐inflammatory effects in dogs. Hypothesis/Objectives – To evaluate the efficacy of PCSO‐524, in combination with oclacitinib in dogs with cAD.
Takeo Nishiyama, Masashi Kusakabe, Ichiro Imanishi, Tadashi Hisano, Teruyasu Fukamachi, Norihito Taguchi, Keita Iyori, Yun‐Hsia Hsiao   +7 more
wiley   +1 more source

A randomised controlled trial testing the rebound‐preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis

Veterinary Dermatology, Volume 34, Issue 2, Page 99-106, April 2023., 2023
Background – A rebound of pruritus occasionally occurs after oclacitinib dose reduction in dogs with atopic dermatitis (AD). Objectives – To determine whether an initial 4‐day course of prednisolone decreases the probability of a pruritus rebound after reducing the frequency of oclacitinib administration.
Thierry Olivry, Viktorija Lokianskiene, Alejandro Blanco, Pablo Del Mestre, Kerstin Bergvall, Luc Beco   +5 more
wiley   +1 more source

A randomised, double‐blinded comparison between subcutaneous rush and intralympathic allergen immunotherapy induction in atopic dogs

Veterinary Dermatology, Volume 34, Issue 2, Page 91-98, April 2023., 2023
Background – Atopic dermatitis (AD) is one of the most common skin diseases in small animal practice. Allergen immunotherapy (AIT) is the only curative treatment for the disease, and oral, subcutaneous and intralymphatic administration of allergens are commonly employed.
Ralf S. Mueller, Yuri Zablotski, Katja Baumann, Teresa Boehm, Bettina Kasper, Christoph Klinger, Maarten Monke, Laura Udraite‐Vovk, Tamara Weitzer, Natalie K. Y. Gedon   +9 more
wiley   +1 more source

The effect of a mixed cannabidiol and cannabidiolic acid based oil on client‐owned dogs with atopic dermatitis

Veterinary Dermatology, Volume 33, Issue 4, Page 329-e77, August 2022., 2022
Background– Cannabidiol (CBD) and cannabidiolic acid (CBDA) are reported to have antinociceptive, immunomodulatory and anti‐inflammatory actions. Objectives – To determine if CBD/CBDA is an effective therapy for canine atopic dermatitis (cAD). Conclusions and clinical relevance – Cannabidiol/CBDA as an adjunct therapy decreased pruritus, and not skin ...
Melissa Loewinger, Joseph J. Wakshlag, Daniel Bowden, Jeanine Peters‐Kennedy, Andrew Rosenberg   +4 more
wiley   +1 more source